fluorouracil has been researched along with Carcinoma 256, Walker in 44 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma 256, Walker: A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The antitumor activity of this compound was superior to those of 5-FU and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur, Ftorafur) in the treatment of transplantable tumors, not only 5-FU-sensitive tumors such as adenocarcinoma 755, lymphosarcoma LS-1, and plasmacytoma X5563, but also 5-FU-resistant tumors such as Lewis lung carcinoma and Walker carcinosarcoma 256." | 3.66 | Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. ( Arakawa, M; Inomata, T; Sasagawa, K; Shimizu, F; Shinkai, K, 1981) |
| "5-Fluorouracil was added into the diffusion cell in combination with vasomodulators or after pretreatment with epinephrine." | 1.46 | Influence of vasomodulators and tumor transplantation on the disposition of 5-fluorouracil after application to the liver surface in rats. ( Fumoto, S; Horishita, M; Kodama, Y; Miyamoto, H; Nakamura, J; Nishida, K; Sasaki, H; Tokunaga, A, 2017) |
| "In the rats bearing the Novikoff hepatoma, both modulators increased the amounts of cyctotoxic anabolites of 5-FU, but at the doses administered, the cumulative amounts of 5-FU anabolites formed after MTX were significantly higher than those formed after TMTX or after saline control." | 1.31 | Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy. ( Berman, E; Chatterjee-Parti, S; Katzir, I; Shani, J; Wolf, W, 2000) |
| " The present study documents that it is now possible to estimate the pharmacokinetic behavior of 5-fluorouracil and of its active metabolites at its target site, tumor tissue, by using noninvasive measurements." | 1.28 | In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ( el-Tahtawy, A; Wolf, W, 1991) |
| " At the 1st hr after dosing the 5-FU level in the small intestine was close to, but that in other tissues was much lower than, the 5-FU level in the tumor of both types." | 1.26 | Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. ( Fukazawa, H; Hongu, Y; Ichihara, S; Shimizu, H; Suzuki, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (81.82) | 18.7374 |
| 1990's | 6 (13.64) | 18.2507 |
| 2000's | 1 (2.27) | 29.6817 |
| 2010's | 1 (2.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasumoto, M | 1 |
| Yamawaki, I | 1 |
| Marunaka, T | 1 |
| Hashimoto, S | 1 |
| Loeffler, LJ | 1 |
| Sajadi, Z | 1 |
| Hall, IH | 4 |
| Lee, KH | 3 |
| Ibuka, T | 1 |
| Mar, EC | 2 |
| Okamoto, M | 1 |
| Wu, YS | 1 |
| Kodama, Y | 1 |
| Horishita, M | 1 |
| Tokunaga, A | 1 |
| Miyamoto, H | 1 |
| Fumoto, S | 1 |
| Sasaki, H | 1 |
| Nakamura, J | 1 |
| Nishida, K | 1 |
| MCNAIR, TJ | 1 |
| WIBIN, FA | 1 |
| HOPPE, ET | 1 |
| SCHMIDT, JL | 1 |
| DEPEYSTER, JA | 1 |
| WOLBERG, WH | 1 |
| JOHNSON, RO | 1 |
| CURRERI, AR | 1 |
| MCBRIDE, TJ | 1 |
| NOBLE, LC | 1 |
| CARR, MA | 1 |
| HULL, K | 1 |
| OLESON, JJ | 1 |
| SMITH, SJ | 1 |
| BUSCH, H | 1 |
| Abraham, D | 1 |
| Carbone, PP | 1 |
| Venditti, JM | 1 |
| Kline, I | 1 |
| Goldin, A | 1 |
| Suzuki, S | 1 |
| Hongu, Y | 1 |
| Fukazawa, H | 1 |
| Ichihara, S | 1 |
| Shimizu, H | 1 |
| Berger, MR | 1 |
| Habs, M | 1 |
| Schmähl, D | 1 |
| Mattern, J | 5 |
| Volm, M | 5 |
| Wayss, K | 5 |
| Weber, N | 1 |
| Arakawa, M | 1 |
| Shimizu, F | 1 |
| Sasagawa, K | 1 |
| Inomata, T | 1 |
| Shinkai, K | 1 |
| Sato, T | 1 |
| Civalleri, D | 1 |
| Esposito, M | 1 |
| De Cian, F | 1 |
| Balletto, N | 1 |
| Vannozzi, MO | 1 |
| Mondini, G | 1 |
| Carrabetta, S | 1 |
| Bocchio, MM | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 1 |
| Fukushima, M | 1 |
| Shimizu, K | 1 |
| Ikenaka, K | 1 |
| Katzir, I | 1 |
| Shani, J | 1 |
| Wolf, W | 2 |
| Chatterjee-Parti, S | 1 |
| Berman, E | 1 |
| Hult, RL | 1 |
| Larson, RE | 1 |
| Faufmann, M | 1 |
| Kozhukhov, AN | 1 |
| Meĭren, DV | 1 |
| Gilev, AP | 1 |
| Mandel, HG | 3 |
| Klubes, P | 3 |
| Fernandes, DJ | 1 |
| Connelly, K | 2 |
| Cerna, I | 2 |
| Geelhoed, GW | 1 |
| Cotino, HH | 1 |
| Zwaveling, A | 1 |
| Kaufmann, M | 1 |
| Jentzsch, K | 1 |
| McSheehy, PM | 3 |
| Prior, MJ | 3 |
| Griffiths, JR | 3 |
| el-Tahtawy, A | 1 |
| Ohkouchi, K | 1 |
| Imoto, H | 1 |
| Takakura, Y | 1 |
| Hashida, M | 1 |
| Sezaki, H | 1 |
| Miwa, M | 1 |
| Nishimura, J | 1 |
| Kamiyama, T | 1 |
| Ishitsuka, H | 1 |
| Kulish, OP | 1 |
| Webber, MM | 1 |
| Verma, R | 1 |
| Chang, B | 1 |
| Chissov, VI | 1 |
| Borisov, VI | 1 |
| Rusakov, IG | 1 |
| Shchitkov, KG | 1 |
| Il'ina, AI | 1 |
| Herrmann, R | 1 |
| Wüst, GP | 1 |
| Karaivanova, MK | 1 |
| Syrkin, AB | 1 |
| Nathanson, L | 1 |
| Cole, DR | 1 |
| Grossi, CE | 1 |
| Conte, AJ | 1 |
| Rousselot, LM | 1 |
1 trial available for fluorouracil and Carcinoma 256, Walker
| Article | Year |
|---|---|
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy | 1997 |
43 other studies available for fluorouracil and Carcinoma 256, Walker
| Article | Year |
|---|---|
Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Fluorouracil; Letha | 1978 |
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
Topics: Acetonitriles; Amino Acids; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Ehrlic | 1977 |
Antitumor agents. 31. Helenalin sym-dimethylethylenediamine reaction products and related derivatives.
Topics: Alkylating Agents; Animals; Carcinoma 256, Walker; Cells, Cultured; Chemical Phenomena; Chemistry; E | 1978 |
Antitumor agents 32. Synthesis and antitumor activity of cyclopentenone derivatives related to helenalin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma 256, Walker; Cells, Cultured; Cyclopentanes; L | 1978 |
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Lactones; Leukemia, Experimental; Male; Melan | 1977 |
Influence of vasomodulators and tumor transplantation on the disposition of 5-fluorouracil after application to the liver surface in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma 256, Walker; Cell Line, Tumor; Epinephrine; Fluo | 2017 |
Antitumor action of several new piperazine derivatives compared to certain standard anticancer agents.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Fluorouracil; Humans; Mechloretham | 1963 |
Controlled-dose therapy as an adjunct to surgery.
Topics: Carcinoma; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Protein Deficiency | 1963 |
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl | 1964 |
EFFECTS OF URACIL MUSTARD ON IN VIVO INCORPORATION OF PRECURSORS INTO NUCLEIC ACIDS OF THE WALKER TUMOR.
Topics: Animals; Carcinoma; Carcinoma 256, Walker; DNA; DNA, Neoplasm; Fluorouracil; Kinetics; Metabolism; N | 1964 |
Evaluation of chemical agents against the plasma cell tumor LPC-1 in mice.
Topics: Alkylating Agents; Animals; Carcinoma 256, Walker; Cyclophosphamide; Electrophoresis; Fluorouracil; | 1967 |
Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.
Topics: Animals; Carcinoma 256, Walker; Female; Floxuridine; Fluorouracil; Male; Mice; Rats; Sarcoma 180; Te | 1980 |
[Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma 256, Walker; Cyclophosphamide; Fe | 1984 |
[Studies in vivo and in vitro on the influence of 5-fluorouracil and n'-(2'-furanidyl)-5-fluorouracil on the walker carcinosarcoma 256 in the rat (author's transl)].
Topics: Animals; Carcinoma 256, Walker; Deoxyuridine; Dose-Response Relationship, Drug; Fluorouracil; Male; | 1980 |
Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma 256, Walker; Female; Fluorouracil; Lung Neoplas | 1981 |
[Circadian chronotherapy for Walker-256 of Wistar rat].
Topics: Animals; Body Weight; Carcinoma 256, Walker; Circadian Rhythm; Combined Modality Therapy; Fluorourac | 1994 |
[In vitro study on intrathecal application of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant tumor].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma 256, Walker; Floxuridine; Fluor | 1998 |
Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Topics: Animals; Carcinoma 256, Walker; Drug Administration Schedule; Fluorine; Fluorouracil; Kinetics; Live | 2000 |
Dissociation of 5-fluorouracil uptake from intracellular pH in Walker 256 carcinosarcoma.
Topics: Animals; Carcinoma 256, Walker; Fluorouracil; Glucose; Hydrogen-Ion Concentration; In Vitro Techniqu | 1976 |
Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Cricetinae; Da | 1975 |
[Pharmacokinetics of ftorafur-2-14C in rats with Walker carcinosarcoma].
Topics: Animals; Carcinoma 256, Walker; Fluorouracil; Male; Mice; Tegafur | 1977 |
Studies of the antitumor action of 5-fluorouracil (FU).
Topics: Animals; Antineoplastic Agents; Bone Marrow; Carcinoma 256, Walker; Colonic Neoplasms; Deoxyuridine; | 1979 |
Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5'-monophosphate and 2-deoxyuridine 5'-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors.
Topics: Animals; Bone Marrow; Carcinoma 256, Walker; Deoxyuracil Nucleotides; Deoxyuridine; DNA, Neoplasm; D | 1978 |
Effects of 5-fluorouracil on human colon carcinoma and solid rat Walker 256 carcinosarcoma: evaluation as in vitro predictors of clinical response.
Topics: Animals; Carcinoma 256, Walker; Colonic Neoplasms; Deoxyuridine; DNA, Neoplasm; Fluorodeoxyuridylate | 1978 |
Treatment of experimental liver tumors by continuous intra-arterial chemotherapy.
Topics: Administration, Oral; Animals; Carcinoma 256, Walker; Fluorouracil; Hepatic Artery; Infusions, Paren | 1976 |
[Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cyclophosphamide; Dactinomycin; D | 1975 |
[Effect of 5-fluorouracil and irradiation of the cell kinetics of Walker carcinoma and the small intestine in rats].
Topics: Animals; Carcinoma 256, Walker; Cell Movement; Epithelial Cells; Epithelium; Fluorouracil; Intestine | 1975 |
Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma 256, Walker; Cell Division; Drug | 1992 |
In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Carcinoma 256, Walker; Fluorine; Fluorouracil; Kinetics; Least-Squares Analysis; Magnetic R | 1991 |
Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system.
Topics: Animals; Carcinoma 256, Walker; Doxorubicin; Female; Fluorouracil; Infusions, Intra-Arterial; Mitomy | 1990 |
Methotrexate increases the activation and cytotoxicity of 5-fluorouracil: detected by 19F n.m.r. in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma 256, Walker; F | 1989 |
Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.
Topics: Animals; Carcinoma 256, Walker; Deoxyuracil Nucleotides; Female; Fluorodeoxyuridylate; Fluorouracil; | 1989 |
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Leukemia L | 1987 |
[Effect high-altitude conditions on the antitumor activity of cyclophosphane and its action on lymphoid tissue cells].
Topics: Altitude; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma 256, | 1985 |
Tumor uptake of 5-fluorouracil, methotrexate, and adriamycin vs gallium.
Topics: Animals; Carcinoma 256, Walker; Doxorubicin; Female; Fluorouracil; Gallium Radioisotopes; Kinetics; | 1986 |
[Experimental evaluation of tumor therapy with cytostatic agents deposited in the abdominal cavity in acetylcellulose].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cellulose; Cyclophosphamide; Delayed-Action P | 1987 |
Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.
Topics: Animals; Carcinoma 256, Walker; Carcinoma, Squamous Cell; Cell Line; Dose-Response Relationship, Dru | 1985 |
[On the question of preclinical selection of cytostatics in the area of treatment of human tumors].
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Culture Te | 1969 |
[Characteristics of growth and sensitivity to cytostatics of Walker 256 carcinosarcoma in randombred and Wistar rats].
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma 256, Walker; Cyclophosphamide; Fluorouracil; M | 1974 |
The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cytarabine; Dauno | 1974 |
[Time factor in evaluating antineoplastic agents].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dactinomycin; Fluorouracil; M | 1972 |
In vivo prediction of drug sensitivity with cancer-seeking isotopes.
Topics: Amides; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; D | 1971 |
Adjuvant intraluminal chemotherapy with 5-fluorouracil in simulated colon cancer in the rat.
Topics: Animals; Carcinoma 256, Walker; Colonic Neoplasms; Fluorouracil; Rats | 1966 |